EP0672123A1 - Proteine de surface multifonctionnelle de streptococci - Google Patents
Proteine de surface multifonctionnelle de streptococciInfo
- Publication number
- EP0672123A1 EP0672123A1 EP93902960A EP93902960A EP0672123A1 EP 0672123 A1 EP0672123 A1 EP 0672123A1 EP 93902960 A EP93902960 A EP 93902960A EP 93902960 A EP93902960 A EP 93902960A EP 0672123 A1 EP0672123 A1 EP 0672123A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- sdh
- protein
- activity
- streptococci
- adp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 102000018697 Membrane Proteins Human genes 0.000 title abstract description 11
- 108010052285 Membrane Proteins Proteins 0.000 title abstract description 11
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 claims abstract description 62
- 230000000694 effects Effects 0.000 claims abstract description 50
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 claims abstract description 50
- 230000027455 binding Effects 0.000 claims abstract description 30
- 108010067306 Fibronectins Proteins 0.000 claims abstract description 26
- 102000016359 Fibronectins Human genes 0.000 claims abstract description 26
- 229960000274 lysozyme Drugs 0.000 claims abstract description 15
- 239000004325 lysozyme Substances 0.000 claims abstract description 15
- 108010014251 Muramidase Proteins 0.000 claims abstract description 14
- 102000016943 Muramidase Human genes 0.000 claims abstract description 14
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims abstract description 14
- 235000010335 lysozyme Nutrition 0.000 claims abstract description 14
- 102000009062 ADP Ribose Transferases Human genes 0.000 claims abstract description 8
- 108010049290 ADP Ribose Transferases Proteins 0.000 claims abstract description 8
- 229960005486 vaccine Drugs 0.000 claims abstract description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 111
- 102000004169 proteins and genes Human genes 0.000 claims description 106
- 238000000034 method Methods 0.000 claims description 36
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 25
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 25
- 239000000203 mixture Substances 0.000 claims description 19
- 101710088194 Dehydrogenase Proteins 0.000 claims description 12
- 230000005764 inhibitory process Effects 0.000 claims description 5
- 241000124008 Mammalia Species 0.000 claims description 4
- 210000004400 mucous membrane Anatomy 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000003381 solubilizing effect Effects 0.000 claims description 2
- 108010020056 Hydrogenase Proteins 0.000 claims 3
- 206010061372 Streptococcal infection Diseases 0.000 abstract description 6
- 238000002360 preparation method Methods 0.000 abstract description 4
- 235000018102 proteins Nutrition 0.000 description 100
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 47
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 32
- 229950006238 nadide Drugs 0.000 description 31
- 239000000872 buffer Substances 0.000 description 27
- LXJXRIRHZLFYRP-VKHMYHEASA-L (R)-2-Hydroxy-3-(phosphonooxy)-propanal Natural products O=C[C@H](O)COP([O-])([O-])=O LXJXRIRHZLFYRP-VKHMYHEASA-L 0.000 description 21
- LXJXRIRHZLFYRP-VKHMYHEASA-N D-glyceraldehyde 3-phosphate Chemical compound O=C[C@H](O)COP(O)(O)=O LXJXRIRHZLFYRP-VKHMYHEASA-N 0.000 description 21
- 241000894006 Bacteria Species 0.000 description 20
- 102000004190 Enzymes Human genes 0.000 description 20
- 108090000790 Enzymes Proteins 0.000 description 20
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 20
- 229940088598 enzyme Drugs 0.000 description 20
- 239000000284 extract Substances 0.000 description 18
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 18
- 235000001014 amino acid Nutrition 0.000 description 17
- 150000001413 amino acids Chemical class 0.000 description 17
- 239000012528 membrane Substances 0.000 description 17
- 238000001262 western blot Methods 0.000 description 17
- 210000004379 membrane Anatomy 0.000 description 16
- 239000000499 gel Substances 0.000 description 15
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 14
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 12
- 241000283973 Oryctolagus cuniculus Species 0.000 description 12
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 12
- 239000007983 Tris buffer Substances 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 12
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 12
- 238000002965 ELISA Methods 0.000 description 11
- 108060008487 Myosin Proteins 0.000 description 11
- 102000003505 Myosin Human genes 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 11
- 230000001580 bacterial effect Effects 0.000 description 11
- 108090000765 processed proteins & peptides Proteins 0.000 description 10
- 239000011780 sodium chloride Substances 0.000 description 10
- 230000005730 ADP ribosylation Effects 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 9
- 230000002255 enzymatic effect Effects 0.000 description 9
- 102000004142 Trypsin Human genes 0.000 description 8
- 108090000631 Trypsin Proteins 0.000 description 8
- 239000002244 precipitate Substances 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 239000012588 trypsin Substances 0.000 description 8
- 108010034119 Myosin Subfragments Proteins 0.000 description 7
- 210000002421 cell wall Anatomy 0.000 description 7
- 238000000605 extraction Methods 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 7
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 7
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 6
- 102000007469 Actins Human genes 0.000 description 6
- 108010085238 Actins Proteins 0.000 description 6
- 102000010831 Cytoskeletal Proteins Human genes 0.000 description 6
- 108010037414 Cytoskeletal Proteins Proteins 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000000020 Nitrocellulose Substances 0.000 description 6
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 229920001220 nitrocellulos Polymers 0.000 description 6
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 241000193385 Geobacillus stearothermophilus Species 0.000 description 5
- 239000002033 PVDF binder Substances 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- 125000003275 alpha amino acid group Chemical group 0.000 description 5
- 230000009257 reactivity Effects 0.000 description 5
- 210000002027 skeletal muscle Anatomy 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 4
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 4
- 241001505901 Streptococcus sp. 'group A' Species 0.000 description 4
- PWJFNRJRHXWEPT-AOOZFPJJSA-N [[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2r,3r,4r)-2,3,4-trihydroxy-5-oxopentyl] hydrogen phosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OC[C@@H](O)[C@@H](O)[C@@H](O)C=O)[C@@H](O)[C@H]1O PWJFNRJRHXWEPT-AOOZFPJJSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 4
- 235000011130 ammonium sulphate Nutrition 0.000 description 4
- 230000001086 cytosolic effect Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 238000010217 densitometric analysis Methods 0.000 description 4
- XEYBHCRIKKKOSS-UHFFFAOYSA-N disodium;azanylidyneoxidanium;iron(2+);pentacyanide Chemical compound [Na+].[Na+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].[O+]#N XEYBHCRIKKKOSS-UHFFFAOYSA-N 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
- 229940012957 plasmin Drugs 0.000 description 4
- 229940083618 sodium nitroprusside Drugs 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 3
- 241000193996 Streptococcus pyogenes Species 0.000 description 3
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 3
- 102000005937 Tropomyosin Human genes 0.000 description 3
- 108010030743 Tropomyosin Proteins 0.000 description 3
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 210000000805 cytoplasm Anatomy 0.000 description 3
- -1 dioxetane anion Chemical class 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000004989 laser desorption mass spectroscopy Methods 0.000 description 3
- 238000004811 liquid chromatography Methods 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 210000004877 mucosa Anatomy 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 210000001938 protoplast Anatomy 0.000 description 3
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- NNRFRJQMBSBXGO-CIUDSAMLSA-N (3s)-3-[[2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-4-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-oxobutanoic acid Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O NNRFRJQMBSBXGO-CIUDSAMLSA-N 0.000 description 2
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 241000698776 Duma Species 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 101001061354 Gallus gallus Glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101001066129 Homo sapiens Glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 229920005654 Sephadex Polymers 0.000 description 2
- 239000012507 Sephadex™ Substances 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 241000589500 Thermus aquaticus Species 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 101710162629 Trypsin inhibitor Proteins 0.000 description 2
- 229940122618 Trypsin inhibitor Drugs 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 238000000376 autoradiography Methods 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000008033 biological extinction Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000000969 egg white Anatomy 0.000 description 2
- 235000014103 egg white Nutrition 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 230000002414 glycolytic effect Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 102000047486 human GAPDH Human genes 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000012933 kinetic analysis Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 108010009719 mutanolysin Proteins 0.000 description 2
- YFCUZWYIPBUQBD-ZOWNYOTGSA-N n-[(3s)-7-amino-1-chloro-2-oxoheptan-3-yl]-4-methylbenzenesulfonamide;hydron;chloride Chemical compound Cl.CC1=CC=C(S(=O)(=O)N[C@@H](CCCCN)C(=O)CCl)C=C1 YFCUZWYIPBUQBD-ZOWNYOTGSA-N 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000012723 sample buffer Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 108010010318 streptococcal M protein Proteins 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000002753 trypsin inhibitor Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- IEQAICDLOKRSRL-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEQAICDLOKRSRL-UHFFFAOYSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- LJQLQCAXBUHEAZ-UWTATZPHSA-N 3-phospho-D-glyceroyl dihydrogen phosphate Chemical compound OP(=O)(O)OC[C@@H](O)C(=O)OP(O)(O)=O LJQLQCAXBUHEAZ-UWTATZPHSA-N 0.000 description 1
- BDDLHHRCDSJVKV-UHFFFAOYSA-N 7028-40-2 Chemical compound CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O BDDLHHRCDSJVKV-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 102000020236 ADP-ribosylarginine hydrolase Human genes 0.000 description 1
- 108010079768 ADP-ribosylarginine hydrolase Proteins 0.000 description 1
- 102220510810 APC membrane recruitment protein 1_F90A_mutation Human genes 0.000 description 1
- 108700023418 Amidases Proteins 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 102000003846 Carbonic anhydrases Human genes 0.000 description 1
- 108090000209 Carbonic anhydrases Proteins 0.000 description 1
- 102000009016 Cholera Toxin Human genes 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- MNQZXJOMYWMBOU-VKHMYHEASA-N D-glyceraldehyde Chemical compound OC[C@@H](O)C=O MNQZXJOMYWMBOU-VKHMYHEASA-N 0.000 description 1
- 101710108485 Envelope phospholipase F13 Proteins 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical group O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 101001027128 Homo sapiens Fibronectin Proteins 0.000 description 1
- 101001018100 Homo sapiens Lysozyme C Proteins 0.000 description 1
- 101000829980 Homo sapiens Ral guanine nucleotide dissociation stimulator Proteins 0.000 description 1
- 125000000570 L-alpha-aspartyl group Chemical group [H]OC(=O)C([H])([H])[C@]([H])(N([H])[H])C(*)=O 0.000 description 1
- 125000000899 L-alpha-glutamyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C([H])([H])C(O[H])=O 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 102000008192 Lactoglobulins Human genes 0.000 description 1
- 108010060630 Lactoglobulins Proteins 0.000 description 1
- 101710085938 Matrix protein Proteins 0.000 description 1
- 101710127721 Membrane protein Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- SOWBFZRMHSNYGE-UHFFFAOYSA-N Monoamide-Oxalic acid Natural products NC(=O)C(O)=O SOWBFZRMHSNYGE-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 108010065081 Phosphorylase b Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- KQHKSGRIBYJYFX-UHFFFAOYSA-J Ponceau S Chemical compound [Na+].[Na+].[Na+].[Na+].Oc1c(cc2cc(ccc2c1N=Nc1ccc(cc1S([O-])(=O)=O)N=Nc1ccc(cc1)S([O-])(=O)=O)S([O-])(=O)=O)S([O-])(=O)=O KQHKSGRIBYJYFX-UHFFFAOYSA-J 0.000 description 1
- 102100023320 Ral guanine nucleotide dissociation stimulator Human genes 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000194026 Streptococcus gordonii Species 0.000 description 1
- 241000588902 Zymomonas mobilis Species 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 102000005922 amidase Human genes 0.000 description 1
- 238000003277 amino acid sequence analysis Methods 0.000 description 1
- 239000001166 ammonium sulphate Substances 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 108010089975 arginyl-glycyl-aspartyl-serine Proteins 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 238000000211 autoradiogram Methods 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940096384 chicken egg white lysozyme Drugs 0.000 description 1
- VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 239000012468 concentrated sample Substances 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000030609 dephosphorylation Effects 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000010799 enzyme reaction rate Methods 0.000 description 1
- 230000006203 ethylation Effects 0.000 description 1
- 238000006200 ethylation reaction Methods 0.000 description 1
- 230000005281 excited state Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000004201 immune sera Anatomy 0.000 description 1
- 229940042743 immune sera Drugs 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229910052816 inorganic phosphate Inorganic materials 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 108091005592 methylated proteins Proteins 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- APVPOHHVBBYQAV-UHFFFAOYSA-N n-(4-aminophenyl)sulfonyloctadecanamide Chemical compound CCCCCCCCCCCCCCCCCC(=O)NS(=O)(=O)C1=CC=C(N)C=C1 APVPOHHVBBYQAV-UHFFFAOYSA-N 0.000 description 1
- TYQCGWOGNUOQAR-ZDUSSCGKSA-N n-[(3s)-1-chloro-5-methyl-2-oxohexan-3-yl]-4-methylbenzenesulfonamide Chemical compound CC(C)C[C@@H](C(=O)CCl)NS(=O)(=O)C1=CC=C(C)C=C1 TYQCGWOGNUOQAR-ZDUSSCGKSA-N 0.000 description 1
- 230000010807 negative regulation of binding Effects 0.000 description 1
- 230000018791 negative regulation of catalytic activity Effects 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 229940101270 nicotinamide adenine dinucleotide (nad) Drugs 0.000 description 1
- 230000014207 opsonization Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 230000010627 oxidative phosphorylation Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920000223 polyglycerol Polymers 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000013014 purified material Substances 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 102220037654 rs587780327 Human genes 0.000 description 1
- 229920006298 saran Polymers 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- OBTWBSRJZRCYQV-UHFFFAOYSA-N sulfuryl difluoride Chemical compound FS(F)(=O)=O OBTWBSRJZRCYQV-UHFFFAOYSA-N 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229960001479 tosylchloramide sodium Drugs 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0008—Oxidoreductases (1.) acting on the aldehyde or oxo group of donors (1.2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y102/00—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2)
- C12Y102/01—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2) with NAD+ or NADP+ as acceptor (1.2.1)
- C12Y102/01009—Glyceraldehyde-3-phosphate dehydrogenase (NADP+) (1.2.1.9)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Definitions
- This invention relates to a surface protein of streptococci which is involved in early colonization of the pharyngeal mucosa. More specifically, it relates to a multifunctional protein which is on the surface of streptococci, including pathogenic streptococci, such as Streptococcus pyogenes and is particularly characterized by its ability to bind fibronectin, lysozyme, and the cyclosketal proteins myosin and actin as well as by its enzyme activity, specifically dose dependent dehydrogenase activity with glyceraldehyde-3-phosphate (GADPH) .
- the molecule also functions as an ADP- ribosylating enzyme and as an ADP-ribosyl transferase.
- compositions and uses of the surface protein including, for example vaccines prepared from the whole protein and segments thereof, particularly conserved segments having activity similar to that of the protein. 2
- Mammalian diseases especially human diseases caused by streptococcal infection with bacteria such as Streptococcus pyogenes are a significant health problem.
- 25 to 35 million cases of group A streptococcal infections which primarily afflict school age children are reported annually (1) .
- the high incidence and potential severity of streptococcal infections provide impetus for development of an effective and safe vaccine to prevent streptococcal related infections.
- SDH streptococcal surface dehydrogenase
- GAPDH proteins are a class of dehydrogenase enzymes intimately involved in mammalian physiological reactions. Generally, members of the class are found in the cytoplasm, but some have been found associated with membranes and cellular cyclosketal structures of eukaryotes.
- the glycolytic enzyme of this invention s believed to be unique n that it s a surface protein of prokaryotes. No other such GAPDH protein has previously been described.
- the GAPDH protein of this invention has some structural characteristics similar to other proteins of the GAPDH family. For example, over 80% of the NH - terminal 18 of 39 amino acids are identical to the GAPDH family of enzymes. However, it differs in many other respects, as will be explained hereinafter. It is, therefore, a novel product which has not heretofore been isolated and characterized.
- a detailed characterization of purified SDH has disclosed that its native conformation is probably a tetramer with a molecular weight of about 156 kDa.
- the molecular weight of the protein by mass spectrometric analysis is about 35.8 kDa.
- SDS PAGE it is about 39.2 kDa.
- the protein has been identified on the surface of Groups A, B, C, E, G, H and L streptococci utilizing affinity purified anti-SDH antibodies.
- the protein exhibited a dose dependent dehydrogenase activity on glyceraldehyde-3-phosphate (G-3-P) in the presence of beta nicotinamide adenine dinucleotide (NAD) .
- G-3-P glyceraldehyde-3-phosphate
- NAD beta nicotinamide adenine dinucleotide
- the multifunctional activity of SDH was revealed by its ability to bind fibronectin and lysozyme as well as the cytoskeletal proteins myosin and actin.
- the binding activity of SDH to myosin was found to be localized to the globular heavy meromyosin domain.
- SDH did not bind to streptococcal M protein, tropomyosin or the coiled- coil domain of myosin.
- the multiple binding capacity of SDH especially in connection with cycloskeletal proteins, in conjunction with its GAPDH activity indicates a role in the colonization, internalization and the subsequent proliferation of streptococci. Trypsin treatment of whole streptococci resulted in a marked reduction in their reactivity to SDH antibodies.
- the inability to remove SDH from the streptococcal surface after washing in 2 M NaCl or 2% SDS indicates that the protein is not peripherally associated but tightly bound to the cell.
- the novel SDH is obtained by solubilizing the selected streptococcus with lysin to produce a mixture containing SDH.
- the SDH may be isolated from the mixture by any of a number of convenient methods known to the skilled artisan including the method illustrated below.
- It may also be produced by transforming an organism such as E. coli with an appropriate gene so that the E. coli will express SDH.
- NAD beta nicotinamide adenine dinucleotide
- PVDF polyvinylidine difluoride
- EDTA Eyhylenediamine tetra acetic acid
- PMSF Paradimethyl sulfonyl fluoride
- TLCK N-p-tosyl-L-lysine chloro-methyl ketone
- SDS Sodium dodecyl sulfate
- Mono Q FPLC Mono Q(Trade Name) Fast protein liquid chromatography
- Superose 12 FPLC Superose-12(Trade Name) Fast protein liquid chromatography
- TSK-Phenyl HPLC TSK-Phenyl (Trade Name) high performance/pressure liquid chromatography
- NADH beta-nicotinamide adeninedinucleotide
- reduced ELISA Enzyme linked im unosorbent assay
- ELIDA Trade name of Physica Inc. Sephadex G-25 PD-10: G-25 PD-10: trade name of
- HEPES (N-[2-hydroxyethyl]piperizine-N , -[2-ethansulfonic acid])
- RGDS Arginine-Glycine-Aspartic acid-Serine (Arg-Gly- Asp-Ser)
- G-3-P Glyceraldehyde-3-phosphate
- GAPDH Glyceraldehyde-3-phosphate dehydrogenase
- Fig. l SDS-polyacrylamide gel (10%) analysis of
- Lane a Lysin extract of D471 streptococci.
- Lane b Precipitate of 65% (NH 4 )_S0 4 saturation of the lysin extract.
- Lane c Precipitate of 85% (NH.J-SO. saturation of the supernatant after 65% precipitation.
- Lane d Pooled Mono Q fractions at 0.28 M gradient elution.
- Lane e Partially purified SDH from the Superose 12 column.
- Lane f Purified SDH from Phenyl TSK column. Arrow marks on lanes a and b at 50 kDa indicate the position of M protein. Prestained marker protein mixture with molecular mass as indicated on the left margin.
- Fig. 2 (a) The NH_-terminal sequence of SDH. (b) Comparison of the NH_-terminal amino acid sequence of SHD with the amino acid sequences of the known GAPDH molecules obtained fr the translated Genbank database.
- Fig. 3 Lineweaver-Burk's double reciprocal kinetic analysis of GAPDH activity of SHD. 25 ug of SDH was assayed as function of G-3-P in the presence of NAD (lOOuM) in triethanolamine-phosphate-EDTA-DTT buffer at pH 8.6. The Km for G-3-P was estimated to be 1.33 uM,
- the Km for NAD was estimated to be 156.7 uM, Vmax:0.459 X l ⁇ "3 M NADH min ⁇ , Intercept on Y axis(1/Vmax) 2.18, and slope (Km/Vmax) 341.74.
- Km for NAD by the method of Michaelis-Menten as shown in the inset was estimated to be 148.86 uM and Vmax: 0.445 X 10 ⁇ 3 M NADH min "1 .
- Fig. 4 (A) Coomassie Blue stain of SDS-gel and (B) Western-blot analysis of SDH with affinity purified anti-SDH antibodies suggesting a multimeric structure for the SDH molecule. Lanes a and d: Crude lysin extract.
- Lanes b and e Purified SDH. Lanes c and f: Unboiled purified SDH in sample buffer without SDS and saturated wit NAD. Arrow mark indicates the position of a molecule of the size consistant with a tetrameric form of SDH. MW markers are indicated on the left margin (Details on each marker-see Fig. 1) .
- Fig. 5 Dot blot immunoanalysis to locate SDH on the streptococcal surface. The assay determines the extent of reactivity of affinity purified anti-SDH antibodies to surface exposed protein before and after 2% SDS, 2M NaCl and trypsin treatments. Dot blots were treated with LumiPhos-530 substrate (41) and developed on X-ray film. Densitometric reading of the image obtained on the X-ray film was expressed as an optical density in terms of arbitrary units measured on an image analyzer using the Dumas program (Drexel University, Philadelphia, USA) . An internal linear standard curve for the optical density 0.008 to 1.333 was obtained for final densitometric analysis of the dot blot. Each bar representes the mean of four to eight separate readings + S.D.
- Fig. 6 GAPDH activity of whole streptococci.
- the GAPDH activity was observed at 340 mn of whole M6 streptococci by determining the conversion of NAD to NADH in the presence of G-3-P. Details of the buffer system is described in materials and methods.
- Fig. 7 (A) Western-blot analysis of lysin extract of various streptococcal M types with affinity purfied anti-SDH antibodies at a 1:2000 dilution of 0.5 mg/ml stock. Purified SDH and an M negative (M ⁇ ) streptococci are also incuded in the analysis. (B) Western-blot analysis of mutanolysin extract of various grouping strains of streptococci using anti-SDH antibodies as described in (A) .
- Fig. 8 Competition kinetic enzyme-linked immunosorbent assays (kELISA) with immobilized SDH.
- GAPDH commercially available purified GAPDH from E ⁇ stearothermophilus, human erythrocytes and rabbit skeletal muscle were used to compete for the binding of affinity purified anti-SDH antibodies (1:1000 dilution of 0.5 mg/ml stock).
- Each curve represents the mean of three separate experiments with less than 5% standard deviaiton (not shown) .
- Inset shows the Western blot of the reactivity of affinity purified anti-SDH antibodies with (a) streptococcal SDH and GAPDHs of (b) bacterial (B. stearothermophilus) , (c) rabbit skeletal muscle and (d) human erythrocytes.
- Fig. 9 Binding of 125I-SDH to cytoskeletal proteins.
- A Coomassie Blue stained SDS-PAGE gel (10%) containing 5 ug protein of various cytoskeletal proteins, lysozyme and M6 protein (43) .
- Lane a rabbit skeletal myosin.
- Lane b heaving meromyosin.
- Lane c light meromyosin.
- Lane d actin.
- Lane e M6 protein.
- Lane f M6 protein.
- Fig. 10 Binding activity of SDH to fibronectin.
- A Coomassie stain of an SDS gel containing 5 ug of SDH and BSA.
- B Western-blot analysis of a duplicate gel showing the binding of fibronectin followed by anti- fibronectin to the SDH molecule.
- C Autoradiograph of a similar Western blot showing the binding of 125I- fibronectin to the SDH protein. Lanes a, c & e - SDH.
- Fig. 11 ADP-ribosylation of SDH.
- Purified SDH (lanes 1, 5 and 9) , crude streptococcal cell wall extract (lanes 2, 6 and 10), cytoplasm (lanes 3, 7 and 11) and membrane (lanes 4, 8 and 12) fractions were incubated with [ 32P]NAD in ADPR buffer. The proteins were then separated on a 12% SDS gel and stained with (A) Coomassie blue.
- B Western blot analysis of a duplicate gel reacted with affinity purified anti-SDH antibodies and
- Fig. 12 ADP-ribosyl transferase activity of SDH.
- Human fibronectin was obtained from Boehringer Mannheim. Goat anti-human fibronectin and affinity purified rabbit anti-goat IgG coupled to alkaline phosphatase were obtained from Sigma. Pre-stained molecular weight standards were purchased from Bethesda
- PVDF membrane ' Immobilon-P' l, was from Millipore. Na 125I was from New England Nuclear. All other chemicals and reagents unless otherwise indicated were purchased from Sigma.
- Group A 5-hemolytic streptococcal strains of various M types and standard strains used for streptococcal grouping were from The Rockefeller University culture collection (New York, NY) and are listed as follows: M2(D626), M4(D896), M5(Manfrando) , M6(D471), M24(CS24), M29(D23), M41(C101/103/4) , M57(A995), M58(D774), M60(D398), M ⁇ (T28/51/4) ; group A, J17A4 (an M- strain) ; group A variant, A486var; group B, 090R; group C, C74; group D, D76; group E, K131; group F, F68C; group G, D166B; group H, F90A; group L, D167B; and group N, C559. Lysin extraction and location of SDH protein:
- a crude extract containing the major surface proteins was prepared using the procedure of lysin extraction to remove the streptococcal cell wall as described before (2) .
- bacteria washed in 50 mM sodium acetate buffer, pH 5.5 were suspended in the same buffer containing 30% raffinose and 5 MM EDTA. Lysin is added to the suspension (1:100 dil; 360 Units) and incubated for 90 min at 37°C with end-to-end slow rotation.
- the resulting protoplasts sedimented at 15,000 X g for 30 min in a Sorvall centrifuge. The supernatant was saved, dialyzed against 25 mM Tris/HCl, pH 8.5,5mM EDTA, concetrated on Amicon PM-10 membrane (Amicon Corp) and used for further purification.
- the pelleted protoplasts were resuspended and lysed in hypotonic buffer (2 MM sodium acetate, pH 5.5, containing 2 mM PMSF, 1 MM TLCK, 10 MM MgCl, and 10 ug/ml DNAse) followed by three freeze/thaw cycles.
- hypotonic buffer (2 MM sodium acetate, pH 5.5, containing 2 mM PMSF, 1 MM TLCK, 10 MM MgCl, and 10 ug/ml DNAse
- the membranes were sedimented at 100,000 x g for 45 min at 4°C.
- the membrane pellet and cytoplasmic extract in the supernatant were analyzed with Coomassie blue stain after separation on SDS gel.
- Membranes were further treated with 1.5 M sodium chloride or 100 mM sodium carbonate, pH 11.3 to determine the nature of association of SDH protein with the membrane.
- lysin extraction of trypsinized bacteria was carried out as described earlier (3). Briefly, washed bacteria were suspended in 100 mM NH.HC0 3 and digested with trypsin (250 ug/ml) at 37°C for 3 hr, after which the trypsin was inactivated by the addition of soybean trypsin inhibitor (200 ug/ml) . Lysin extracts of trypsinized and control non-trypsinized bacteria were compared for the loss or reduction in the size of SDH protein.
- Lysin extraction was used as the starting material for the purification of the SDH.
- the dialyzed, concentrated, lysin extract was precipitated at 60% saturation of ammonium sulf te at 4°C.
- the precipitates were centrifuged at 6,000 X g for 20 min and the supernatant was brought to 85% saturation of ammonium sulfate.
- the resulting precipitate was dialyzed against 25 mM Tris/HCl buffer pH 8.5, 5 mM EDTA and passed over to Mono Q FPLC column (Pharmacia LKB Biotechnology Inc.) equilibrated with the same dialyzing buffer.
- NH_-terminal amino acid sequence was determined according to the method of Matsudaira et al (4) . Briefly, the purified SDH was separated on a pre- electrophoresed 10% acrylamide-SDS gel under non- denaturing condition and then transferred to PVDF Immobilon-P filter pre-wetted in ethanol. Protein was visualized by 0.05% Coomassie blue in 50:40 methanol, water, acetic acid solvent mixture. The blots were destained in methanol: water: acetic acid (50:40:10).
- the portion of the membrane containing the SDH band was excised and subjected to automated Edman degradation on an Applied Biosystem model A470 sequenator. Each band contained about 2-3 ug protein as determined by BCI protein estimation method (Pierce) .
- the PVDF membrane containing the SDH was stained with 0.1% Ponceau-S (Sigma) in 1% acetic acid.
- the section of membrane containing the protein band was excised and destained with water. This section of membrane was hydrolyzed in 6N HCl/phenol at 110°C for 22 hr. Amino acids were separated on Waters Novapek C8 column analyzed with Waters Maxima software, 510 pump and 490 detector. Cysteine content was analyzed also from the PVDF bound carboxyamide methylated protein as described by Crestfield (5) . All analyses were performed by Protein Biotechnology Facility of the Rockefeller University. .
- Glyceraldehyde-3-phosphate Dehydrogenase (GAPDH) Activity is:
- GAPDH assay was carried out according to the method originally described by Samuel (7) with a minor modifications. Since GAPDH catalyzes the oxidative phosphorylation of D-G-3-P to form 1,3-diphosphoglycerate in the present of NAD and inorganic phosphate, the assay solution was made of triethanolamine (40 mM) , Na.HPO. (50 mM) and EDTA (5 mM) .
- Disposable semi-micro 1.5 ml capacity spectrophotometer cuvette contained 7ul G-3-P (Sigma, 49 mg/ml) , 100 uM NAD (Boehringer Mannheim) and assay buffer to a final volume of 1.0 ml after the addition of enzyme source with pH of the mixture being 8.6. Different concentrations of SDH were used to plot the standard curve for the absorbance at 340 nm per minute as a measure of conversion of NAD to NADH using Spectronic 3000 spectrophotometer (Milton Roy) .
- GAPDH activity for SDH was measured in the lysin extract, ammonium sulphate precipitate and pooled fraction at various purification stages.
- New Zealand white rabbits were immunized subcutaneously with 200 ug of purified SDH emulsified in Freund's complete adjuvant (1:1) at multiple sites. Rabbits were boosted once with 200 ug of this protein in Freund's incomplete adjuvant (1:1). All rabbits were bled 3 weeks after the first and 10 days after the second immunization. All sera were filter sterilized and stored at 4°C.
- the surface location of SDH was determined with the monospecific antibodies using a bacterial dot-blot immunoassay as previously described (10) .
- an overnight culture of strain D471 was adjusted to OD g5 _ n 1.0 with 50 mM Tris/HCl buffer, pH 8.5. Aliquots of this suspension were centrifuged and resuspended to the same volume of buffer containing either 2 M NaCl or 2% SDS, and rotated at room temperature for 1 h, centrifuged, and the respective supernatants were saved. After washing, the pellets were again adjusted to 0D g50 nm 1.0 with 50 mM Tris/HCl buffer, pH 8.5.
- the bacterial suspension in the Tris/HCl buffer was centrifuged, and the bacteria were suspended in 100 mM NH 4.HCO3- to nm 1.0 and treated with trypsin (250 ug/ml) for 3 h at 37 C. Trypsin activity was inhibited with trypsin inhibitor as described above, and the bacteria were pelleted and resuspended in the
- Tris/HCl buffer to OD 6 c 50 n nm 1.0 50 ul of each bacterial suspension was transferred to nitrocellulose paper using dot-blot assembly (Bio-Rad Laboratories, Richmond, CA) . Reactivity of surface-exposed epitopes of the 39-kD protein was determined using affinity-purified anti-SDH protein antibodies (1:1,000 dilution of 0.5 mg/ml stock).
- a duplicate blot was developed wi .th Lumi.-PhosTm530 (Adamantyl-1,2- dioxetane phenylphosphate; Lumigen Inc., Detroit, MI), which undergoes enzyme (alkaline phosphatase)-catalyzed dephosphorylation to form a dioxetane anion that is converted ultimately into an excited state of the methyl meta-oxybenzoate anion, the light emitter.
- the developer was then drained off, and the wet blot wrapped in Saran Wrap was exposed to x-ray film for 20 min and developed using conventional procedures.
- Densitometric analysis of each spot on the x-ray film was carried out on an image analyzer using the conventional procedures. Densitometric analysis of each spot on the x-ray film was caried out on an image analyzer using the Dumas program (Drexel University, Philadelphia, PA) interfaced with IBM computer.
- a whole cell assay was developed to determine whether SDH on the surface of streptococci serves as an active GAPDH enzyme.
- Different concentrations of trypsinized and non-trypsinized streptococci were incubated with and without G-3-P in presence of NAD in triethanolamine-phosphate-EDTA-DTT buffer as described above in a final volume of 1.0 ml for a period of 2 min at room temperature and centrifuged to pellet out the bacteria.
- the supernatants were analyzed for the conversion of NAD to NADH by recording absorbance at 340 nm.
- This enzymatic activity was also determined on streptococci preincubated with 1:50 dilution (1 mg/ml) of purified anti-SDH antibodies as prepared above to determine specific inhibition of enzymatic activity.
- Electrophoresis, Western blotting of lysin extraction and protein samples at different purification stages were carried out as described earlier (2,3).
- Lysin extracts of M serotypes 2, 4, 5, 6, 24, 29, 41, 57, 58, 60, and M ⁇ were prepared as described (2).
- the muralytic enzyme mutanolysin (20 ug/ml; sigma Chemical Co.) was used to prepare cell wall extracts of each grouping strain suspended in 50 mM Tris/HCl buffer, pH 6.8, containing 5 mM EDTA, 5 mM MgCl_, and 30% raffinose, and incubated at 37°C for 60 min under . constant end-to-end rotation. Proteins in all the extracts were separated on SDS-PAGE and transferred to nitrocellulose. The blots were probed with affinity- purified anti-SDH protein antibodies as described above.
- B.stearothermophilus were determined both on Western blot and competitive ELISA as described below.
- Affinity purified antibodies were adjusted to a dilution that gave an ELISA reading of 1.0 at 405 nm after 60 min.
- ELISA was performed following standard procedures except that ELISA plates were coated with 100 ul/well of 1 ug/ml SDH for 3 hr at 37°C followed by overnight at 4°C. Competition of GAPDH from different bacterial as well as mammalian origin containing cross reactive epitopes for the binding of Anti-SDH antibodies was performed as described previously (10) . Briefly, ELISA plates were coated as described above with SDH. Optimum dilution of affinity purified antibodies as determined above was used.
- Competing GAPDH were serially diluted in antibody diluting buffer containing 0.05% Brij-35 pH 7.4 (10) at decreasing molar excess relative to SDH starting with 100 X molar excess.
- Anti-SDH antibodies were then added in each well and the plates were processed and finally developed and binding of these proteins was determined by kinetic ELISA as described (11) using ELIDA 5 microtitre plate reader Physics Inc. (20) at 405 nm.
- SDH was labeled with 125I by the chloramine-T method using Iodobeads (Pierce Chemical Co.).
- the labeled protein was separated from free iodine by filtration over a column of Sephadex G-25 (PD-10, Pharmacia LKB Biotech Inc) and collected in 10 mM HEPES buffer saline pH 7.4 containing 10 mM MgCl_, 2 mM CaCl_, 50 mM KC1 and 150 mM NaCl.
- the labeled protein was stored at -20°C in aliquots containing 0.02% NaN_.
- Fibronectin and plasmin were labeled essentially by the same method.
- the specific activities of SDH, fibronectin and plasmin were, respectively, 2X10 5 , 1.0X10 6 and 1.21X10 6 CPM/ g.
- the Binding activity of SDH and fibronectin was determined by the use of radioactive proteins. Egg white-lysozyme and/or cytoskeletal proteins (myosin, heavy meromyosin (HMM) , light chain myosin (LMM) , tropomyosin, and actin) all of which obtained from Sigma, were electrophoresed on 10% SDS-PAGE gels and electroblotted on nitrocellulose paper.
- cytoskeletal proteins myosin, heavy meromyosin (HMM) , light chain myosin (LMM) , tropomyosin, and actin
- the blots were blocked in 10 mM HEPES buffer containing 15 mM NaCl, 0.5% Tween-20, 0.04% NaN 3 and 0.5% BSA pH 7.4 for 2-3 hr at room temperature and probed for 3-4 hr at room temperature in the same buffer contai .ni.ng 125I- fibronectin, 125I-plasmin at 3X105CPM/ml.
- the probed blots were then washed 3-4 times with blocking buffer.
- Autoradiography were prepared by exposing the dried nitrocellulose blots to Kodak Blue Brand film with an intensifying screen for 36-48 hour at -70 C.
- the ADP-ribosylation of SDH was performed as described (15) with slight modification. Briefly, the standard reaction mixture (0.2 ml) contained 100 mM Tris/HCl at pH 7.4, 10 mM dithiothreitol, 1 mM NADP, 10 mM thymidine (ADPR buffer) . After the addition of 10 uM
- the GAPDH activity of purified SDH and the ADP- ribosylated SDH was measured by the method originally described by Fritz (7) and modified as described (16) . Briefly, the reaction was performed in a final volume of 1 ml containing 800-850 ul of buffer (40 mM triethanolamine, 50 mM Na.HP0 4 , 5 mM EDTA, pH 8.6),
- Sodium nitroprusside was freshly diluted in ADPR buffer (200 ul) to a final concentration of 2 mM and preincubated for 2 minutes at room temperature before the addition of 30 ug of SDH and [ 32 P]-NAD to start the ADP- ribosylation reaction. At different time intervals, 40 ul aliquots were removed and precipitated with TCA. A parallel control representing the same quantity of SDH and [ 32P]-NAD were incubated in the absence of sodium nitriprusside and aliquots were taken at the same time intervals as the test samples. Precipitated proteins were separated on SDS gel and autoradiographed. In a similar set of experiments, ADP-ribosylation was also performed using 200 ul of a streptococcal lysin extract in ADPR buffer incubated in the presence and absence of 2 mM sodium nitroprusside.
- SDH protein was precipitated from the lysin extract by first precipitating non-specific proteins at 60% saturation of ammonium sulfate followed by 85% saturation. The SDH was found in the 85% ammonium sulfate precipitate (Fig. 1) .
- the dialyzed precipitate was applied to a Mono Q FPLC column and the proteins eluted with an NaCl gradient from 0 mM to 300 mM. SDH eluted at a salt concentration of about 280 mM. Fractions with fibronectin binding activity were pooled, dialyzed and further purified on a Superose-12 FPLC molecular sieving column.
- NH,-terminal amino acid sequence analysis of the purified SDH confirmed the homogeneity of the preparation resulting in a single amino acid at nearly all positions (Fig. 2a) . Except for positions 31 and 35, a single amino acid was identified in the first 35 residues with the remaining four tentatively identified.
- the amino acid composition of the purified protein indicated a high content of Asp/Asn (12.1%), followed by Ala (10.7%), Gly (10.3%), Val (10.2%), and Glu/Gln (8.4%).
- the mass of the purified protein 35,882 daltons as determined by laser desorption mass- spectrometry was used to more precisely assign the number of residues/mol (Table 1) .
- Antibodies to SDH were affinity purified on SDH- bound to activated gluteraldehyde beads followed by a protein A column.
- the resultant purified anti-SDH IgG recognized only the SDH protein band (Fig. 4) .
- Dot-Blot immunoassay was applied to determine the location of SDH on streptococcal surface. Results revealed that trypsin treated streptococci were markedly reduced in their reactivity to anti-SDH IgG (Fig. 5) . To determine if the
- SDH protein is peripherally bound to the cell wall or tightly bound, the streptococcal cells were washed with 2M NaCl and 2% SDS. The results revealed that the SDH was not extractable by the high salt or ionic detergent.
- Fig. 6 Data presented in Fig. 6 revealed a dose dependent GAPDH activity catalyzed by the whole organisms. As found with the purified SDH, the intact bacteria also did not catalyze the reaction in absence of the specific substrates G-3-P and NAD (Fig. 6a) . The enzymatic activity on the whole organisms was also found to be partially (30%) but specifically inhibitable by anti-SDH IgG (Fig. 6c) . Enzymatic activity was found to be decreased by 80% when trypsinized bacteria were used in the reaction mixture (Fig. 6b) . The background 20% activity suggested an incomplete digestion of SDH protein by trypsin.
- SDH protein ubiquitous nature of the SDH protein in different streptococcal M serotypes was determined by Western blot analysis of lysin extracts using affinity purified anti-SDH IgG. As shown in Fig. 7, SDH protein was found in several serotypes. Furthermore, all were found to be of same molecular weight without any indication of size variation.
- the fibronectin binding activity of SDH was determined both by using 125I-labeled fibronectin or fibronectin-anti-fibronectin on a Western blot. The results revealed that the SDH protein was able to bind fibronectin in both assays (Figs. 10b and c) .
- SDH is a major surface protein of streptococci, including group A streptococci and has both enzyme activity and multiple binding activity. No such protein has previously been detected, isolated and characterized.
- the novel surface protein is principally characterized by its ability to bind fibronectin, lysozyme and cycloskeletal protein as well as by its enzymatic activity as a GAPDH. Its molecular weight is approximately 39 kDa. The first fifteen amino acid residues at the amino terminal are:
- GAPDH 100% homology with the bacterial form of GAPDH and 80-90% homology with eukaryotic or fungal GAPDH.
- SDH is, however, significantly different from previously recorpted GAPDHs, because the high homology of the first fifteen amino acid residues is not preserved towards the carboxy end of the molecule and the amino acid composition varies appreciably from other GAPDHs.
- SDH also functions as an ADP-ribosylating enzyme which, in the presence of NAD, is auto-ADP-ribosylated. It has been found that in a crude lysin extract of group A streptococci containing a mixture of cell wall associated molecules, SDH is the only molecule that is
- ADP-ribosylated Treatment of ADP-ribosylated SDH with the cytoplasmic fraction of Group A removed the ADP- ribosye of SDH which indicates the presence of SDH specific ADP-ribosyl hydrolase in the cytoplasmic compartment. Treatment of purified SDH or the crude lysin extract with sodium nitroprusside, which spontaneously generates nitric oxide, was found to stimulate the ADP-ribosylation of SDH in a time dependent manner. Both ADP-ribosylation and nitric oxide treatment inhibited the glyceraldehyde-3-phosphate dehydrogenase activity of SDH.
- SDH does not represent a single protien, but rather a class of surface proteins of streptococci, all of which have similar properties.
- the protein is involved in the colonization and probably in the internalization and proliferation of group A streptococci.
- the enzyme activity of SDH may be involved in the binding of the bacteria to endothelial cells by reaction of an aldehyde reduction product of teichoic acid which is a polyglycerol phosphate.
- the aldehyde function could bind the bacteria to the tissue surface by reaction with amino group on that surface.
- proteins, polypeptides and peptides of this invention may be obtained by any of a number of known processes.
- the protein can be isolated as described above. Alternativley, the protein or segments thereof can be prepared by recombinant DNA techniques. For example, the gene for the protein or an oligonucleotide for the desired segment can be inserted into a plasmid and the plasmid used to transform E. coli so that the bacteria will express the desired product.
- Polypeptide and peptides within the scope of the invention containing, for example from about 6 to 20 or more amino acid segments may be synthesized by standard solid phase procedures with appropriate amino acids using the protection, deprotection and cleavage techniques and reagents appropriate to each specific amino acid or peptide.
- a combination of manual and automated (e.g.. Applied Biosystem 430A) solid phase techniques can be used to synthesize the novel peptides of this invention.
- Altough less convenient, classical methods of peptide synthesis can also be employed.
- the products of the invention are amphoteric. They can exist and be utilized as free bases or as pharmaceutically acceptable metallic or acid addition salts.
- Suitable metallic salts include alkali and alkaline earth metal salts, preferably sodium or potassium salts.
- Acid addition salts may be prepared from a wise variety of organic and inorganic acids including mineral acids, for example citric, lactic, aleic, tartaric, phosphoric and hydrochloric acids. These salts can be prepared by procedures well known to those skilled in the art.
- cholera toxin B For use as a vaccine, it is presently preferred to administer the selected product conjugated to a carrier such as cholera toxin B.
- a carrier such as cholera toxin B.
- the protein or segment thereof may also be administered as a hybrid protein expressed on a streptococcal surface utilizing the procedure of Pozzi et al (17,18).
- the presently preferred method for the administration of the vaccines of the invention is by the intranasal route, but the invention is not so limited. Other parenteral or oral prcoedures may be employed.
- the patient to be protected will be treated with an amount of SDH or other product of the invention which is effective to elicit a protective immune response.
- the selected agent may be administered alone or in a pharmaceutically acceptable liquid or solid carrier in which it may be dispersed, dissolved or suspended. If, for example, the patient is to be treated intravenously, the peptide may be suspended as a free base or dissolved as a metallic salt in isotonic aqueous buffer.
- Other methods of treatment and pharmaceutically acceptable carriers will be apparent to the skilled artisan.
- proteins, polypeptides and peptides of this invention and the genes or oligonucleotides which are employed in their expression are useful as probes for genes and proteins. They are also useful to raise antibodies by which specific strains of streptococci can be identified. For example in tests for mammalian infections.
- D-glyceraldehyde-3- phosphate dehydrogenase the purification and characterization of the enzyme from the thermophiles Bacillus stearothermophilus and Thermus aquaticus. Eur. J. Biochem. 108:535.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Enzymes And Modification Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
L'invention concerne une nouvelle protéine de surface streptococcique se caractérisant principalement par son pouvoir à lier les fibronectines et les lysozymes, mais qui possède également une activité glycéraldéhyde-3-phosphate déshydrogénase, une activité de ribosylation d'ADP et une activité ADP-ribosyl transférase. Cette protéine est notamment utile dans la préparation des vaccins pour assurer une protection contre les infections streptococciques.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US81817092A | 1992-01-08 | 1992-01-08 | |
US818170 | 1992-01-08 | ||
US91373292A | 1992-07-15 | 1992-07-15 | |
US913732 | 1992-07-15 | ||
PCT/US1993/000082 WO1993014198A1 (fr) | 1992-01-08 | 1993-01-07 | Proteine de surface multifonctionnelle de streptococci |
Publications (1)
Publication Number | Publication Date |
---|---|
EP0672123A1 true EP0672123A1 (fr) | 1995-09-20 |
Family
ID=27124235
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP93902960A Withdrawn EP0672123A1 (fr) | 1992-01-08 | 1993-01-07 | Proteine de surface multifonctionnelle de streptococci |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0672123A1 (fr) |
JP (1) | JPH07502896A (fr) |
AU (1) | AU668908B2 (fr) |
CA (1) | CA2127550A1 (fr) |
WO (1) | WO1993014198A1 (fr) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5928900A (en) * | 1993-09-01 | 1999-07-27 | The Rockefeller University | Bacterial exported proteins and acellular vaccines based thereon |
TW448185B (en) * | 1993-11-05 | 2001-08-01 | Lilly Co Eli | Vaccine design and production |
US5846547A (en) * | 1996-01-22 | 1998-12-08 | Regents Of The University Of Minnesota | Streptococcal C5a peptidase vaccine |
US6355255B1 (en) | 1998-12-07 | 2002-03-12 | Regents Of The University Of Minnesota | Streptococcal C5a peptidase vaccine |
US6245335B1 (en) | 1996-05-01 | 2001-06-12 | The Rockefeller University | Choline binding proteins for anti-pneumococcal vaccines |
US6890539B2 (en) | 1998-12-22 | 2005-05-10 | Microscience, Ltd. | Genes and proteins, and their use |
DK1141308T3 (da) | 1998-12-22 | 2007-06-04 | Microscience Ltd | Gruppe B streptococcus proteiner og deres anvendelse |
CN1733800A (zh) * | 1998-12-22 | 2006-02-15 | 微科学有限公司 | 外表面蛋白质及其基因和用途 |
US7256265B2 (en) | 1999-12-03 | 2007-08-14 | Regents Of The University Of Minnesota | Streptococcal C5a peptidase vaccine |
DK1294771T3 (da) | 2000-06-12 | 2008-12-15 | Univ Saskatchewan | Kimært GapC-protein fra Streptococcus og anvendelse deraf til vaccinering og diagnosticering |
AR074273A1 (es) | 2008-11-05 | 2011-01-05 | Wyeth Corp | Composicion inmunigenica de multiples componentes para la prevencion de la enfermedad estreptococica beta-hemolitica bhs. uso. metodo |
CN111198271B (zh) * | 2018-11-16 | 2023-04-28 | 山东泽济生物科技有限公司 | 一种用于甘油醛-3-磷酸脱氢酶检测的化学发光酶联免疫试剂盒 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2035039C (fr) * | 1989-06-21 | 2000-02-01 | Vincent A. Fischetti | Poxvirus recombinant et vaccin dirige contre la proteine m des streptocoques |
-
1993
- 1993-01-07 WO PCT/US1993/000082 patent/WO1993014198A1/fr not_active Application Discontinuation
- 1993-01-07 EP EP93902960A patent/EP0672123A1/fr not_active Withdrawn
- 1993-01-07 CA CA002127550A patent/CA2127550A1/fr not_active Abandoned
- 1993-01-07 AU AU34351/93A patent/AU668908B2/en not_active Ceased
- 1993-01-07 JP JP5512544A patent/JPH07502896A/ja active Pending
Non-Patent Citations (1)
Title |
---|
See references of WO9314198A1 * |
Also Published As
Publication number | Publication date |
---|---|
JPH07502896A (ja) | 1995-03-30 |
CA2127550A1 (fr) | 1993-07-22 |
WO1993014198A1 (fr) | 1993-07-22 |
AU668908B2 (en) | 1996-05-23 |
AU3435193A (en) | 1993-08-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Lu et al. | Yellow jacket venom allergens, hyaluronidase and phospholipase: sequence similarity and antigenic cross-reactivity with their hornet and wasp homologs and possible implications for clinical allergy | |
Williamson et al. | A genetically engineered vaccine against the alpha-toxin of Clostridium perfringens protects mice against experimental gas gangrene | |
US7981432B2 (en) | Proteins within the type E botulinum neurotoxin complex | |
AU668908B2 (en) | Multifunctional surface protein of streptococci | |
WO1999037326A1 (fr) | Hemagglutinine biologiquement active tiree du clostridium botulinum de type a et procedes d'utilisation | |
Marty et al. | Topography of the membrane-bound ADP/ATP carrier assessed by enzymic proteolysis | |
US5869064A (en) | Protein rib, a cell surface protein that confers immunity to many strains of the group B Streptococcus: process for purification of the protein, reagent kit and pharmaceutical composition | |
Motin et al. | V antigen-polyhistidine fusion peptide: binding to LcrH and active immunity against plague | |
Hoffman | Allergens in Hymenoptera venom XVI: Studies of the structures and cross-reactivities of vespid venom phospholipases | |
Flores et al. | Structural analysis and demonstration of the 29 kDa antigen of pathogenic Entamoeba histolytica as the major accessible free thiol‐containing surface protein | |
US6869787B2 (en) | Ricin vaccine and methods of making and using thereof | |
EP1019085B1 (fr) | Formes non anaphylactiques d'allergenes et leurs utilisations | |
JP2947882B2 (ja) | ヘメンテリアギリアニイという南アメリカ蛭からの抗転移素、ギランテン | |
JP2001515728A (ja) | ヘリコバクターウレアーゼの安定化 | |
EP0362274B1 (fr) | Traitement et diagnostic du fourchet utilisant la protease basique de bacteroides nodosus | |
WO2002022679A2 (fr) | Alleles des proteines allergeniques de $i(phleum pratense) | |
RU2719164C1 (ru) | Способы производства протеолитически процессированных полипептидов | |
HINATA et al. | Chemical characterization of rabbit α2-macroglobulin | |
CA2477094A1 (fr) | Vaccin a base de ricin et ses procedes de fabrication et d'utilisation | |
Torres-Ruiz | Structure and function of ribulose 1, 5-bisphosphate carboxylase/oxygenase from Chromatium vinosum | |
WO1998001754A1 (fr) | Nouvelles proteines dans le complexe neurotoxine botulique de type e | |
AU681130C (en) | Protein rib, a cell surface protein that confers immunity tomany strains of the group B streptococcus; process for purification of the protein, reagent kit and pharmaceutical composition | |
JP2002512528A (ja) | ストレプトコッカス イクイの保護m−様タンパク質をコードする化合物及びその検定 | |
Vosti | The characteristics of M proteins purified by column chromatography with hydroxyapatite from acid extracts of Streptococcus pyogenes of types 1, 3, 6, 12 and 17 | |
Beachey | Protective Immunogenicity of Chemically Synthesized Peptide Fragments of Group A Streptococcal M Proteins |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19940708 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE |
|
17Q | First examination report despatched |
Effective date: 19990121 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 19990601 |